The healthcare delivery market is undergoing dramatic change, adapting to survive in a much tougher business climate we call Healthcare 2.0. This should prompt pharma organizations to reevaluate the assumptions on which they’ve built their commercial model, or they risk falling behind the curve.
Dr Andree Bates looks at the impact of precision medicine on pharma and the change in mindset necessary to fit this new reality.
There is an epidemic of sticking roughly to the previous year's plan and budget. This may be useful if that approach is getting you to be the top brand, but if your results are not radically improving you need to examine both your strategy and budget allocation carefully.
by Paul Simms
Rice Powell, Chairman of the Board and CEO for Fresenius Medical Care, speaks to Paul Simms, eyeforpharma Chairman. Fresenius Medical Care is a company well-known for being the first to successfully pioneer a vertically-intergrated, service-oriented model within healthcare.
by Jeff Elton
As we enter into the "Value Era", innovating and delivering value is about understanding critical connections, gaps, and potential solutions or alternatives to each. Jeff Elton discusses the exciting emergence of a truly global health services solutions market.
Although the exchanges have the potential to expand the market for some therapeutic areas, the way in which they are designed will likely have an impact on consumer purchasing behavior. Manufacturers need to understand how consumers are responding and what these changes mean for their business.
Female millennials matter because they are more highly educated than previous generations (according to research) and are set to represent 25% of the global workforce by 2020. However, meeting their employer expectations is a challenge that requires deep insight into their behaviors and motivations.
Biosimilars face a dual challenge of competing with the original product’s clinical and marketing profile, i.e. are they both biosimilar and market similar. In this competitive environment, whatever approach biosimilar manufacturers select must demonstrate how their product adds value.
Following her keynote presentation at eyeforpharma Barcelona 2014, Jane Griffiths, Janssen Company Group Chairman, EMEA, was interviewed by Paul Simms, eyeforpharma Chairman, and discusses how the pharmaceutical industry needs to build trust through collaboration.
by David Laws
This common refrain is often used to justify pharma pricing but it is not doing pharma any favors when it comes to public opinion.
by Marc Yates
In part 2 of the ASEAN series, Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.
Demonstrating value and capturing that value as a revenue stream are key challenges facing Value Added Services creators.
by David Laws
Individual companies need to embrace the issue of trust and not wait for the industry as a whole to act.
Despite all the launch experience in the industry, launches today face very different needs than ones of the past. With the hyper-competitive markets we are now facing, drug launches today have to be focused on value and be able to convince physicians, patients and payers on value.
by David Laws
What does that even mean? Patricia Seybold, Founder of Customers.com, once wrote “fasten your seatbelts!......Why? Because we’re in the midst of a profound revolution. And it’s bigger than the internet revolution or the mobile wireless revolution. It’s a customer revolution".